Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of “Buy” from Brokerages

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have received a consensus recommendation of “Buy” from the six analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $54.20.

A number of research analysts have commented on TARS shares. Oppenheimer increased their price objective on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. The Goldman Sachs Group upped their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of institutional investors have recently modified their holdings of TARS. Assenagon Asset Management S.A. boosted its stake in Tarsus Pharmaceuticals by 0.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,146,812 shares of the company’s stock valued at $63,499,000 after acquiring an additional 5,565 shares during the period. Harbor Capital Advisors Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 22.1% in the 4th quarter. Harbor Capital Advisors Inc. now owns 22,113 shares of the company’s stock worth $1,224,000 after purchasing an additional 4,008 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Tarsus Pharmaceuticals by 2,088.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after purchasing an additional 420,057 shares during the period. Lord Abbett & CO. LLC grew its stake in Tarsus Pharmaceuticals by 28.4% during the 3rd quarter. Lord Abbett & CO. LLC now owns 594,876 shares of the company’s stock worth $19,565,000 after buying an additional 131,636 shares during the last quarter. Finally, Exome Asset Management LLC acquired a new stake in Tarsus Pharmaceuticals in the third quarter worth $1,500,000. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals stock opened at $46.52 on Friday. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.14. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The stock has a market cap of $1.78 billion, a P/E ratio of -12.21 and a beta of 1.02. The stock has a 50 day moving average of $51.01 and a 200-day moving average of $38.14.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.